Promising pharmacological targets include glial inflammatory pathways: dopamine receptor D3 signaling in astrocytes promoted neuroinflammation [154], whereas dopamine D1 receptor agonists improved neuroinflammation in AD and consecutive Aβ1-42-induced cognitive impairment [155]. The gene discussed is DRD1; the disease is Alzheimer disease.